Context: Rosuvastatin is a cholesterol lowering drug. It belongs to class statin. It is prescribed to the patients of coronary artery disease; atherosclerosis; thrombosis; increased low-density-lipoprotein; lipid and triglyceride. Aims:It is a newer drug in market and studies over the pharmacodynamics and pharmacokinetics are in progress. Statin therapy is a long term treatment for which its behavior in the presence of other agents is necessary. For this purpose present study is based on the interaction of the drug with essential and trace elements present in human body or co-administered during multivitamin therapy. Settings and Design: Complexes of rosuvastatin with Cd(II), Cr(II), Mn(II), Fe(III), Co(II), Ni(II) and Zn(II) i.e., metals commonly present in multivitamins, were synthesized in laboratory. Methanolic solution of rosuvastatin with metal chloride salts was reacted. Methods and Material: Reaction between drug and metals was carried out in thermostat at 80 o C for five hours with timely TLC monitoring for completion of reaction. These newly synthesized complexes were identified by IR and NMR spectroscopy and CHN elemental microanalysis and the structure of complexes was proposed. Results: Analyses suggest two molecules of rosuvastatin co-ordinate with the central metal atom through their carboxylic group. CS Chem3D ultra suggests square planner structure of the complex. Conclusions: Synthesis of compounds proposes that rosuvastatin can bind to metals as ligand through its pharmocophore site that may lead to reduced activity of drug and metal both. The study is precursor to in vitro and in vivo study of interaction of drug and metals.
INTRODUCTION
Biosynthesis of cholesterol is a natural phenomenon and gets completed in lever in 25 steps. 1, 2 Disorder in any of the steps may cause over or under production of cholesterol that may lead ultimately to athero sclerosis, thrombosis or coronary artery disease, depending on disorder. 3, 4 Statins are the class of drugs that inhibit HMG CoA reductase, a rate limiting enzyme, competi tively during mevalonate pathway in the synthesis of cholesterol in hepatocytes. Rosuvastatin is a synthetic drug of this class. 5 It is newer drug with 20% bioavail ability 6, 7 and 19 hours elimination halflife. 8 Like other statins it principally reduces total cholesterol (in hypercholesterolemia), LDL cholesterol (in hyperlipoproteinemia), triglycerides (in hypertriglyceridemia), lip ids (in dyslipidemia) and increases HDL cholesterol (in hypolipoprteinemia) 9 to cure atherosclerosis, thrombosis 3 and coronary artery disease. 4 Long term statin therapy usually needs coadministration of different classes of drugs 10 and multivitamins that include essential and trace elements. 11, 9 Most often the combination of drugs inside body may either increase or reduce the efficacy of either drug or themselves; or may cause any side effects; or may be support Submission Date: 16-10-2016 ; Revision Date: 25-11-2016 ; Accepted Date: 27-11-2016 ive in any other activity. Itraconazole increases peak plasma concentration of rosuvastatin when taken simultaneously. 12 Gemfibrozil affects the phar macodynamics activity of rosuvastatin. 13, 14 It in combination with digoxin may cause rhabdomyolysis 15, 16 while supporting anticoagulant effect of warfarin is seen with rosuvastatin. 17 Studies carried out by Edwin and coworkers in 2015 reported decrease in trace elements level in CAD patients. 18 These metals in the presence of chelating agents may cause chelation and complexation instead of working at the targeting site 19 and may reduce their or drug's efficacy. Still there is no such study present that may expose the utilization of metals or rosuvastatin other than target site, when taken in combination. Hence synthesis and characterization of new metal complexes with rosuvastatin becomes important for understanding drugmetal ion interaction and their potential pharmacological use. Synthesis and characterization of metal complexes of rosuvastatin have been reported here.
MATERIALS AND METHODS
Following instruments were used throughout the experiment: UVVisible double beam spectrophotometer 1800 (Shimadzu, Japan); FTIR spectrophotometer Prestige21 200 VCE (Shimadzu, Japan), 1 H NMR (Bruker) AMX 300 MHz spectrometer using TMS as an internal standard; LabPro TM conductometer (Vernier, Oregon); CHN microanalyser (Carlo Erba 1106); melting point appa ratus (Gallenkamp, England), electrical balance Libror AEG120 (Shimadzu, Japan); pH meter (Jenway, UK) and ground glass distillation assembly (Quick fit) (Redleys discovery techniques, UK).
Chemicals and reagents
Rosuvastatin was provided by the courtesy of Pharm Evo Pvt. Ltd., Karachi, Pakistan. All chemicals and reagents of analytical grade were purchased from Sigma Aldrich (Germany) and Merck (Germany).
Mole ratio determination
Conductometric titration was carried out using metal chlorides solutions of 1mM and titrated with 1 mM rosuvastatin ligand at 25 o C to identify the stoichiomet ric ratio of drug and metals. 20, 21 Drug (40 mL) was taken into a flask and 2 mL of metal chloride was added and conductance values were noted until the graph showed chemical equilibrium. Titration curves were plotted between conductance and volume of titrant (metal chloride) 22 ,23 ( Figure 1 ). Confirmation of results was made with job's plot (method of continuous variation) on UVvisible spectrophotometer.
22,23

Drug-metal reaction
Syntheses of complexes of rosuvastatin with metal salts were carried out in 1:2 mole ratios of drug and metal. After dissolving calculated mass of reacting species in suitable solvent system, 23 drops of orthophosphoric acid was added. The reaction flask was set to reflux for 3 hours at 80 o C. The completion of reaction was confirmed by methanol-chloroform (4:6) TLC system. Solutions were then filtered, evaporated and con centrated under reduced pressure. Precipitates were re-crystallized for purification. Their melting points and physical characteristics were obtained.
Spectral studies of complexes
Complexes were characterized by FTIR spectropho tometer in the region of 4004000 cm 1 using KBr disk method and 1 H NMR. Spectra of NMR were recorded as chemical shift in parts per million relative to TMS as an internal standard in CDCl 3 as solvent. Significant 1 H NMR data are tabulated in the order of number of protons and multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; and m, multiplet). Molecular modelling was carried out through CS Chem3D Ultra, version 8 (Cambridge Soft Corporation, Cambridge, MA, USA) software.
RESULTS
Physicochemical and spectroscopic characteristics of rosuvastatin and its complexes have been determined and scheduled in Table 1 and 2 respectively. 
Spectroscopic studies of Rosuvastatin-metal complexes
IR studies: In the IR spectrum of rosuvastatin, there is characteristic broad region of carboxylic OH at 3625 3200 cm 1 and so carboxylic carbonyl stretch at 1654 cm 1 . Asymmetric and symmetric strong stretching vibra tions of sulphonamide are seen at 1336 and 1155 cm 1 respectively. Methyl and methylene bending vibrations are present at 1453 and 1438 cm 1 . Phenyl C=C vibra tions are observed at 1511 cm 1 . Stretch due to CF is seen at 1230 cm 1 . 24 For complexes, all the spectra fol low similar regular change in spectrum of rosuvastatin. The band present in rosuvastatin (36253200 cm −1 ) has been slightly shifted or broadened towards lower frequencies. Carbonyl peak is also disturbed and deshaped that corresponds to the bond formation at carboxylic site. (Figure 2a The metal-complexes in general have similar findings in their spectra. The peak for carboxylic OH proton is found beyond 10.25 ppm in all spectra of complexes suggesting down fielding effect. The protons of -CH 2 adjacent to carboxylic acid group have also been shifted away from TMS. Rest other signals are found at their positions in spectrum of rosuvastatin (Table 4) . CHN elemental microanalysis: The found and cal culated percentages of CHN elemental data are in well agreement with each other and prove the proposed chemical formula of the complex (Table 5, Figure 3 ).
DISCUSSION
The long elimination halflife and bioavailability of rosu vastatin expose it as a superstatin (Hamelin, 1998) . 26 From metabolic study of rosuvastatin it is clear that it majorly remains unchanged. 1 Literature survey reveals that CYP 2C9 enzymes metabolize it very minutely; even then it has shown interaction with some drugs with adverse effects. 12 Interaction of rosuvastatin is reported with glimepiride (Galani and Vyas, 2010), 27 clopidogrel 28 and gemfibrozil. 14 Warfarin has supporting impact on rosuvastatin. 29 Erythromycin 30 and finofibrate 31 have not shown interaction. Some protease inhibitors also interact with rosuvastatin. 32 However, prior to this no such study has been reported for the interaction of rosuvastatin with metals (coadministered in the form of multivitamins). The structure activity relationship of rosuvastatin suggests that it has a chemical structure consisting variety of electron donating sites responsible for multiple interactions and bonding with its substrate. Deficiency of metals inside body i.e. below their limits lead to reduced physiological functions. It becomes multifac eted to understand the interaction of rosuvastatin with different metals and causes of toxicity onto the body. 22, 23 Accordingly the objective of the present research was to analyse the interaction of rosuvastatin with selected metals for multitherapy. Since it is prescribed in oral dosage form, there are chances of its interaction at any stage of administration, dissolution, absorption and distribution prior to its target site since metals easily search compounds for chelation or complexation.
The physicochemical study of rosuvastatin suggests that it is very sparingly soluble in water. The drug is soluble in methanol and ethanol. 26 It shows rapid solu bility in chloroform and DMSO. Its stability was checked by melting point (taking twice with the difference of two days. It can withstand as solid at room temperature (25 o C). It absorbs UV radiations at 241243 nm due to π-π* transition between carbonyl oxygen and unsatu rated carbon of pyrimidine ring, as a consequence of conjugation of lone pair of nitrogen. 33 The physicochemical characteristics of the metalcom plexes have been scheduled in Table 2 . Distinguished properties of these compounds prelude to new com plexes formed. The peak at 241 nm in UVspectra of the complexes indicates that no change in bonding has taken place at pyrimidine site. The complexes formed are unstable and cannot withstand at high heat for which their crystallography was not possible. However the assignments of IR bands were made by comparing the vibrations of complexes with those of the drug. Major absorption bands and frequencies of rosuvastatin (Table 1 ) and corresponding assignments are discussed below and scheduled in Table 3 .
In metal complexes of rosuvastatin, it is found that the band due to carboxylic OH has shifted towards lower frequencies or the band has broadened. In spectra of all complexes, there is slight shift in frequencies of carbonyl of carboxylic acid towards lower wave numbers with reduced peak intensity. Deshaping of carbonyl peak at 1639 cm 1 in spectrum of nickel complex of rosuvastatin is seen. Rest of the peaks are undisturbed.
It shows that rosuvastatin has interaction to the metal ion at oxygen of carboxylic OH site (Table 3) . On comparing the spectra of complexes and drug, all the signals of 1 H NMR of free ligand (rosuvastatin) are present in the spectra of complexes except for changes in proton signals of carboxylic group. The downfield shift of these carboxylic protons suggests that they have been deshielded by metal ligand attracted to its oxygen. The signals for phenyl and pyrimidine are unchanged since they are far from binding site of ligand. The reso nance of protons of CH 2 (3.56 ppm) adjacent to car boxylic acid protons have been shifted downfield due to deshielding effect due to attraction of metal towards carboxylic group in spectra of all complexes. The 1 H NMR analysis confirms the carboxylic group of rosu vastatin as binding site of metal central atom (Table 4) . The CHN elemental analysis (Table 5) . Studies suggest that rosuvastatin chelates with the central metal atom through carboxylic oxygen. Two molecules of rosuvas tatin coordinate with central metal forming square planner complex. The structure is proposed in Figure 3 .
CONCLUSION
Results from syntheses show that metals and rosuvastatin get engaged by complexation when coadministered. Rosuvastatin can bind to either of the coadministered studied compounds prior to binding to the target enzyme HMG CoA reductase at its heptenoic acid site leaving the drug unavailable to bind with its respective receptors to trigger the action. Occurrence of this event could possibly decrease the clinical efficacy of drug. Hence studies suggest that concomitant use of rosuvas tatin and metal salts could pose many side effects in the body and could decrease the efficacy of both. Further synthesis of these new complexes is precursor towards investigation of the in vitro and then in vivo biological evaluation of these compounds.
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SUMMARY Pictorial Abstract
• Cholesterol biosynthesis is a natural phenomenon.
When deposition of excess cholesterol in body causes heart related and vascular diseases and disorders, it becomes necessary to reduce the synthesis of cholesterol. Rosuvastatin is a synthetic drug and belongs to class Statins. This class of drugs mimics the activity of HMG Co A Reductase enzyme during cholesterol synthesis in hepatocytes.
• The current project is study over the behaviour of the drug in presence of trace metals co-administered for combination therapy. For this purpose methanolic solution of rosuvastatin was reacted with metal salts at 80 oC for five hours in laboratory. The completion of reaction was monitored by TLC and compound identification was carried out with IR, 1H NMR and elemental analysis. Chemical structure of compounds formed was proposed through CS Chem3D ultra software.
• The studies suggest that the consumption of active site (heptenoic acid side-chain) of drug with metal ions may leave the drug inactive for its actual target and its efficacy may reduce. 
